TBPH vs ZYME
TBPH: A commercial-stage biopharmaceutical company primarily focused on its COPD therapy, YUPELRI, currently navigating a strategic review and pending merger. ZYME: A clinical-stage biotechnology firm building value through a portfolio of novel multifunctional biotherapeutics and strategic royalty assets.
Side-by-side fundamentals
| Metric | TBPH | ZYME | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $17.03 | $28.12 | |
| Market cap | $884M | $2.0B | |
| P/E as of 2026-10-21 | 16.38 (earnings are mostly non-operating: 107% of trailing pre-tax income, to 2026-06-30) | n/a | |
| Net margin FY2025, SEC XBRL | +98.5% | -76.6% | TBPH higher |
| Operating margin FY2025, SEC XBRL | -3.4% | -87.3% | TBPH higher |
| ROE FY2025, SEC XBRL | +35.7% | -30.2% | TBPH higher |
| ROA FY2025, SEC XBRL | +21.8% | -23.4% | TBPH higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +66.9% | +38.9% | TBPH higher |
| Revenue CAGR (3y) SEC XBRL | +27.9% | -36.4% | TBPH higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.57 | 0.86 | |
| 1-year return as of 2026-10-21 close | +21.6% | +56.8% | ZYME higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.